Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.65 |
| ▸ | FPR2 | P25090 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | PPARG | P37231 | 2/20 | 0.51 |
| ▸ | PPARA | Q07869 | 1/20 | 0.51 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7751730 | 0.85 | LDHA (0.67) | LDHAFPR2KMT2ACA2PPARG | |
| SCHEMBL2029603 | 0.85 | LDHA (0.67) | LDHAFPR2KMT2ACA2PPARG | |
| SCHEMBL7751726 | 0.85 | LDHA (0.67) | LDHAFPR2KMT2ACA2PPARG | |
| SCHEMBL16063575 | 0.85 | LDHA (0.67) | LDHAFPR2KMT2ACA2PPARG | |
| SCHEMBL995624 | 0.85 | LDHA (0.67) | LDHAFPR2KMT2ACA2PPARG | |
| SCHEMBL23797845 | 0.84 | LDHA (0.65) | LDHAFPR2KMT2ACA2PPARG | |
| Hydrochloric Acid SCHEMBL7319633 | 0.84 | LDHA (0.65) | LDHAFPR2KMT2ACA2PPARG | |
| Hydrochloric Acid SCHEMBL7319628 | 0.84 | LDHA (0.65) | LDHAFPR2KMT2ACA2PPARG | |
| SCHEMBL1097490 | 0.83 | LDHA (0.63) | LDHAFPR2KMT2ACA2PPARG | |
| SCHEMBL1395877 | 0.83 | FPR2 (0.67) | LDHAFPR2KMT2ACA2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807664-B2 | Method for producing cyclic organic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-07 | — | — | US | disclosed |
| US-11807664-B2 | Method for producing cyclic organic compound | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-11-07 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20210147475-A1 | METHOD FOR PRODUCING CYCLIC ORGANIC COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2021-05-20 | — | — | US | disclosed |
| EP-2813512-B1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-03-31 | — | — | EP | disclosed |
| US-8980843-B2 | Leptin agonist and methods of use | Temple University—Of the Commonwealth System of Higher Education (US) | 2015-03-17 | — | — | US | disclosed |
| EP-2482833-A1 | LEPTIN AGONIST AND METHODS OF USE | Temple University Of The Commonwealth System Of Higher Education (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20120108504-A1 | LEPTIN AGONIST AND METHODS OF USE | TEMPLE UNIVERSITY-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2012-05-03 | — | — | US | disclosed |
| US-8034365-B2 | Polymer substituted with amide or thioamide groups; vascular stents, bioreabsorbable polymers | REVA MEDICAL, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| WO-2011002673-A1 | LEPTIN AGONIST AND METHODS OF USE | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-01-06 | — | — | WO | disclosed |
| US-20080187567-A1 | N-SUBSTITUTED MONOMERS AND POLYMERS | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2008-08-07 | — | — | US | disclosed |
| US-20080112999-A1 | N-SUBSTITUTED MONOMERS AND POLYMERS | REVA MEDICAL, INC. (US) | 2008-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080187567-A1 | N-SUBSTITUTED MONOMERS AND POLYMERS | NANS, NCL, PNISR | LDHA 1971/4885FPR2 1194/4885KMT2A 3118/4885 |
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | LDHA 3482/4885FPR2 743/4885KMT2A 1875/4885 |
| US-20210147475-A1 | METHOD FOR PRODUCING CYCLIC ORGANIC COMPOUND | SCTR, CTRC, DCXR | LDHA 3832/4885FPR2 2129/4885KMT2A 4076/4885 |
| US-11807664-B2 | Method for producing cyclic organic compound | SCTR, CTRC, DCXR | LDHA 3832/4885FPR2 2129/4885KMT2A 4076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.